Ask AI
ProCE Banner Activity

Evolving Frontiers in Locally Advanced and Metastatic Bladder Cancer: Advances, Challenges, and the Path Toward Personalized Care

Clinical Thought

Get expert insights from a recent live symposium with a focus on recent changes in the therapeutic landscape, biomarker-driven decision-making, and ongoing challenges in optimizing care for patients with muscle-invasive or metastatic bladder cancer.

Released: April 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc. and Astellas Inc.

Astellas Inc.

Pfizer Inc.

Target Audience

This activity is intended for oncologists, urologists, and other healthcare professionals who care for patients with urothelial carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal first-line therapy for patients with la/mUC based on updated guidelines, clinical data, and patient-specific factors

  • Sequence second- and later-line therapies for patients with la/mUC using evidence-based and biomarker-informed strategies

  • Apply multidisciplinary approaches to manage and monitor treatment-related adverse events

  • Implement shared decision-making and caregiver engagement strategies to support personalized care for patients with la/mUC

Disclosure

Primary Author

Fed Ghali, MD: consultant/advisor/speaker: Ferring, Onviv, UroGen.

Petros Grivas, MD, PhD, FASCO: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Foundation Medicine, Gilead, Janssen, Lilly, Merck Sharp & Dohme, Natera, Pfizer, Replimune, Roche, Strata Oncology, Tyra Biosciences, Urogen; researcher: Acrivon, ALX Oncology, Bristol Myers Squibb, EMD Serono, Genentech, Gilead, Merck Sharp & Dohme.

Shilpa Gupta, MD: consultant/advisor/speaker: Astellas, Bristol Myers Squibb, Johnson & Johnson, Merck, Novartis, Pfizer.